Physician profile
Wayne Rubinstein
NPI 1427036011
$3,933.69
in general payments reported to CMS, 2019-2025
21 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $187 · 2021: $402 · 2022: $72.27 · 2023: $558 · 2024: $768 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $892.24 | 2019-2025 | Inspire |
| Biogen, INC. | $646.86 | 2019-2021 | |
| Emd Serono, INC. | $358.88 | 2019-2020 | |
| Banner Life Sciences, LLC | $327.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $308.65 | 2019-2025 | Xywav |
| Abbvie INC. | $214.90 | 2021-2024 | |
| Genzyme Corporation | $189.68 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $138.14 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $130.21 | 2024-2025 | Lumryz |
| Lilly USA, LLC | $126.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $118.04 | 2019-2020 | |
| Ucb, INC. | $103.15 | 2019 | |
| Abbott Laboratories | $86.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $65.85 | 2019 | |
| Genentech USA, INC. | $54.19 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noctrix Health, INC. | $40.35 | 2025 | Nidra |
| Janssen Pharmaceuticals, INC | $31.85 | 2020 | |
| Axsome Therapeutics, INC. | $30.07 | 2024 | Sunosi |
| Alexion Pharmaceuticals, INC. | $27.83 | 2019 | |
| Livanova USA, INC. | $23.82 | 2019 | |
| Lundbeck LLC | $18.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.